Back to List View Graph View

PARP inhibitor

Poly(ADP-ribose) polymerase (PARP) inhibitors are a class of targeted anticancer agents that exploit defects in DNA damage repair pathways, particularly homologous recombination (HR).

Where the papers sit

15 papers from the last 6 months study PARP inhibitor directly · updated from PubMed 16 Nov 2026

  • Homologous Recombination in Cancer

    Homologous-recombination defects and genomic instability are being developed as guides to PARP inhibitor sensitivity across ovarian and cervical cancers. Profiling focuses on DNA-repair lesions, with CCNE1 and TP53 among recurrent genomic features, while HRR hyperactivation is proposed as a vulnerability in neuroendocrine cervical carcinoma. Resistance is linked to POSTN+ myofibroblasts and a STING-WNT immunosuppressive axis, and mitochondrial NADP(H)-dependent dTMP synthesis can blunt PARP inhibitor cytotoxicity. Single-stranded DNA gaps are emerging as a functional response biomarker, but the clinical value of these signatures remains under validation.

    7 papers · 46.7%

  • PARP Therapy in Cancer

    Biomarker-selected PARP inhibition is being tested in BRCA-altered and triple-negative breast cancer, while combination strategies extend into other tumors. DA1 is aimed at BRCA-proficient triple-negative disease through PI3K/AKT/mTOR suppression, and TSL-1502 is being evaluated in germline BRCA-mutated, HER2-negative advanced breast cancer. PARP inhibition also enhances HER3-DXd activity in non-small cell lung cancer. The cluster joins targeted drug discovery with early clinical testing, but its cross-tumor evidence does not establish a single winning regimen.

    4 papers · 26.7%

  • PARP1 Drug Development

    PARP1 drug development is moving toward potent oral inhibitors with CNS penetration and greater enzyme selectivity. Mechanistic work points to p300 inhibition as a way to reverse resistance driven by an acidic microenvironment. Clinical studies address real-world PARP inhibitor use in prostate cancer and rechallenge after platinum-sensitive ovarian cancer, including overall survival and renewed response. The field is balancing next-generation pharmacology with cautious reuse of established agents.

    4 papers · 26.7%

PARADIGM SHIFT

PARP inhibitor response is not determined by homologous-recombination status alone

The study of mitochondrial NADP(H)-dependent de novo dTMP biosynthesis in PARP-inhibitor-non-responsive tumor cells 42784515Sep and the study of acidic-microenvironment-induced resistance in epithelial ovarian cancer 42467549Jul show that PARP-inhibitor resistance can arise independently of homologous-recombination status. Instead of treating HR deficiency as a sufficient explanation for response, these studies identify mitochondrial nucleotide metabolism and an acidic ERK–p300–PARP1 signaling axis as separate resistance mechanisms; accordingly, effective treatment may require cotargeting STAT3 or p300 alongside PARP.

Papers

The 15 papers from the last 6 months that study PARP inhibitor directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Homologous Recombination in Cancer (7)
  1. Assessment of genomic instability and homologous recombination repair in ovarian cancer using the Oncomine Comprehensive Assay Plus. Oncotarget · 5 Nov 2026 PMID 42985963
  2. Molecular profiling of ovarian cancer is feasible and provides valuable therapeutic and research information to women in Aotearoa New Zealand. The New Zealand medical journal · 23 Oct 2026 PMID 42912973
  3. Multi-omics profiling reveals homologous recombination repair hyperactivation as a therapeutic vulnerability in neuroendocrine cervical carcinoma. Signal transduction and targeted therapy · 4 Oct 2026 PMID 42830288
  4. Mitochondrial NADP(H)-dependent de novo dTMP biosynthesis counteracts the cytotoxicity of PARP inhibitors. Proceedings of the National Academy of Sciences of the United States of America · 24 Sept 2026 PMID 42784515
  5. Detection of Single-Stranded DNA Gaps Reveals a Functional Biomarker of Therapeutic Response. Cancer research · 8 Sept 2026 PMID 42708806
  6. Genomic profiling identifies actionable DNA-repair defects in a new cervical cancer model. Scientific reports · 29 Jul 2026 PMID 42527451
  7. Genomic instability drives POSTN+ myofibroblasts via STING-WNT axis to promote immunosuppression and PARPi resistance in ovarian cancer. Science translational medicine · 27 May 2026 PMID 42202048
PARP Therapy in Cancer (4)
  1. PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer. Cell reports. Medicine · 21 Aug 2026 PMID 42628527
  2. Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer. Signal transduction and targeted therapy · 9 Aug 2026 PMID 42572030
  3. Discovery of DA1 as PARP inhibitor for the treatment of BRCA-proficient triple negative breast cancer by suppressing the PI3K/AKT/mTOR signaling pathway. Bioorganic & medicinal chemistry · 30 Jul 2026 PMID 42531674
  4. Integrating Machine Learning and Structure-Guided Discovery of a Novel Type II SYK Inhibitor for Treating Triple-Negative Breast Cancer. Journal of medicinal chemistry · 17 Jun 2026 PMID 42304805
PARP1 Drug Development (4)
  1. Discovery of Potent, Orally Bioavailable, and CNS-Penetrant 1,2,3-Triazolopyridinyl Piperazine-Based PARP1-Selective Inhibitors. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018572
  2. Patterns of Poly(ADP-Ribose) Polymerase Inhibitor Use and Overall Survival in United States Veterans With Prostate Cancer. Clinical genitourinary cancer · 27 Aug 2026 PMID 42660761
  3. Benefits of PARP inhibitor rechallenge in patients with platinum-sensitive recurrent ovarian cancer previously treated with a PARP inhibitor: a multicenter retrospective study. International journal of clinical oncology · 7 Aug 2026 PMID 42566090
  4. Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance. Cancer research · 17 Jul 2026 PMID 42467549

By study type

Clinical trials (1)
  1. Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer. Signal transduction and targeted therapy · 9 Aug 2026 PMID 42572030
Observational studies and case reports (2)
  1. Patterns of Poly(ADP-Ribose) Polymerase Inhibitor Use and Overall Survival in United States Veterans With Prostate Cancer. Clinical genitourinary cancer · 27 Aug 2026 PMID 42660761
  2. Benefits of PARP inhibitor rechallenge in patients with platinum-sensitive recurrent ovarian cancer previously treated with a PARP inhibitor: a multicenter retrospective study. International journal of clinical oncology · 7 Aug 2026 PMID 42566090
Human data, design not indexed (2)
  1. Assessment of genomic instability and homologous recombination repair in ovarian cancer using the Oncomine Comprehensive Assay Plus. Oncotarget · 5 Nov 2026 PMID 42985963
  2. Molecular profiling of ovarian cancer is feasible and provides valuable therapeutic and research information to women in Aotearoa New Zealand. The New Zealand medical journal · 23 Oct 2026 PMID 42912973
Preclinical: animal, cell and lab studies (10)
  1. Discovery of Potent, Orally Bioavailable, and CNS-Penetrant 1,2,3-Triazolopyridinyl Piperazine-Based PARP1-Selective Inhibitors. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018572
  2. Multi-omics profiling reveals homologous recombination repair hyperactivation as a therapeutic vulnerability in neuroendocrine cervical carcinoma. Signal transduction and targeted therapy · 4 Oct 2026 PMID 42830288
  3. Mitochondrial NADP(H)-dependent de novo dTMP biosynthesis counteracts the cytotoxicity of PARP inhibitors. Proceedings of the National Academy of Sciences of the United States of America · 24 Sept 2026 PMID 42784515
  4. Detection of Single-Stranded DNA Gaps Reveals a Functional Biomarker of Therapeutic Response. Cancer research · 8 Sept 2026 PMID 42708806
  5. PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer. Cell reports. Medicine · 21 Aug 2026 PMID 42628527
  6. Discovery of DA1 as PARP inhibitor for the treatment of BRCA-proficient triple negative breast cancer by suppressing the PI3K/AKT/mTOR signaling pathway. Bioorganic & medicinal chemistry · 30 Jul 2026 PMID 42531674
  7. Genomic profiling identifies actionable DNA-repair defects in a new cervical cancer model. Scientific reports · 29 Jul 2026 PMID 42527451
  8. Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance. Cancer research · 17 Jul 2026 PMID 42467549
  9. Integrating Machine Learning and Structure-Guided Discovery of a Novel Type II SYK Inhibitor for Treating Triple-Negative Breast Cancer. Journal of medicinal chemistry · 17 Jun 2026 PMID 42304805
  10. Genomic instability drives POSTN+ myofibroblasts via STING-WNT axis to promote immunosuppression and PARPi resistance in ovarian cancer. Science translational medicine · 27 May 2026 PMID 42202048